Description

Librela Injection (Bedinvetmab)

First-in-class anti-nerve growth factor (NGF) monoclonal antibody injection for monthly control of canine osteoarthritis pain.

Manufactured/Marketed by: Zoetis Inc.
Country of Origin: USA
Dosage form: Injectable solution for subcutaneous use

Presentation:

Single-use vial containing 1 ml solution.
Available strengths: 5 mg/ml, 10 mg/ml, 15 mg/ml, 20 mg/ml and 30 mg/ml bedinvetmab.

Ingredients & Composition:

Each ml contains:
Bedinvetmab – 5 mg, 10 mg, 15 mg, 20 mg or 30 mg (depending on vial strength)
Sterile injectable formulation

Description / Action:

Librela contains bedinvetmab, a caninised monoclonal antibody designed to reduce osteoarthritis-associated pain in dogs.

Bedinvetmab selectively binds to nerve growth factor (NGF), preventing NGF from activating its receptors involved in pain signalling. By neutralising NGF activity, it helps reduce chronic pain associated with canine osteoarthritis and improves mobility.

Class:

Anti-NGF monoclonal antibody (mAb), analgesic for osteoarthritis pain management

Indication / Uses:

For dogs:

Control of pain associated with osteoarthritis

Improvement of mobility and quality of life in dogs suffering from degenerative joint disease

Dosage and administration:

Administer by subcutaneous injection once monthly.
Minimum recommended dose: 0.5 mg/kg body weight every month
Dose according to body weight using appropriate vial strength.
Use entire vial contents after puncture.

Librela dosing table

Dog body weight (kg) Number and strength (mg/ml) of Librela vials to be administered

5–10 kg     1 vial of 5 mg/ml (orange)
10.1–20 kg         1 vial of 10 mg/ml (blue)
20.1–30 kg         1 vial of 15 mg/ml (green)
30.1–40 kg         1 vial of 20 mg/ml (gold)
40.1–60 kg         1 vial of 30 mg/ml (purple)
60.1–80 kg         2 vials of 20 mg/ml (gold)
80.1–100 kg       1 vial of 20 mg/ml (gold) + 1 vial of 30 mg/ml (purple)
100.1–120 kg     2 vials of 30 mg/ml (purple)

Overdose / Side effects / Contraindications / Warnings:

Possible side effects: Urinary tract infection, Bacterial skin infection, Dermatitis or skin irritation, Increased blood urea nitrogen (BUN), Lethargy, Loss of appetite, Vomiting or diarrhoea, Increased drinking or urination, Urinary incontinence, Weakness or difficulty standing, Balance problems or trouble walking and Seizures (rare)

Contraindications:

Do not use in dogs with known hypersensitivity to bedinvetmab.
Do not use in dogs intended for breeding.
Avoid use in pregnant or lactating dogs.
Not recommended in dogs below 12 months of age.

Warnings:

For use in dogs only.
Not for human use.
Avoid accidental self-injection.
Discuss concurrent medicines before use, including NSAIDs, corticosteroids or other monoclonal antibody therapies.

Pharmaceutical precautions / Instructions:

Store refrigerated at 2°C–8°C (36°F–46°F). Do not freeze.
Store in original package to protect from light.
Once punctured, use immediately and discard remaining solution.
Administer only under veterinary supervision.

Safety: Age / Pregnancy / Withdrawal:

Age: Do not use in dogs younger than 12 months.
Pregnancy: Not established; avoid use in pregnant animals.
Lactation: Avoid use in nursing dogs.
Breeding animals: Not recommended.
Withdrawal: Not applicable (companion animal product).

Substitute:

No direct generic substitute currently available. Similar osteoarthritis pain management alternatives: